214 related articles for article (PubMed ID: 27145802)
1. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.
Üçeyler N; Biko L; Hose D; Hofmann L; Sommer C
Mol Pain; 2016; 12():. PubMed ID: 27145802
[TBL] [Abstract][Full Text] [Related]
2. Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease.
Hofmann L; Karl F; Sommer C; Üçeyler N
PLoS One; 2017; 12(6):e0180601. PubMed ID: 28662189
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
4. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
5. Characterization of small fiber pathology in a mouse model of Fabry disease.
Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
Elife; 2018 Oct; 7():. PubMed ID: 30328411
[TBL] [Abstract][Full Text] [Related]
6. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
7. Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for Fabry disease.
Noben-Trauth K; Neely H; Brady RO
Hear Res; 2007 Dec; 234(1-2):10-4. PubMed ID: 17933476
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.
Lakomá J; Rimondini R; Ferrer Montiel A; Donadio V; Liguori R; Caprini M
Mol Pain; 2016; 12():. PubMed ID: 27531673
[TBL] [Abstract][Full Text] [Related]
9. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
[TBL] [Abstract][Full Text] [Related]
11. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
12. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
13. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
15. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.
Lakomá J; Rimondini R; Donadio V; Liguori R; Caprini M
PLoS One; 2014; 9(10):e108641. PubMed ID: 25337704
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
17. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
18. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
Choi S; Kim JA; Na HY; Cho SE; Park S; Jung SC; Suh SH
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):81-9. PubMed ID: 24158513
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease.
Toyooka K
Handb Clin Neurol; 2013; 115():629-42. PubMed ID: 23931807
[TBL] [Abstract][Full Text] [Related]
20. Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
Heare T; Alp NJ; Priestman DA; Kulkarni AB; Qasba P; Butters TD; Dwek RA; Clarke K; Channon KM; Platt FM
J Inherit Metab Dis; 2007 Feb; 30(1):79-87. PubMed ID: 17189993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
